Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 4/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | MERTK | Q12866 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.32 |
| ▸ | GRM5 | P41594 | 2/20 | 0.31 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31474599 | 0.80 | GRM5 (0.32) | S1PR5GRM5 | |
| SCHEMBL8052339 | 0.75 | TNKS (0.39) | GRM5 | |
| SCHEMBL31474627 | 0.74 | S1PR1 (0.30) | S1PR5 | |
| SCHEMBL31670523 | 0.74 | S1PR5 (0.31) | S1PR5S1PR3 | |
| SCHEMBL31474609 | 0.74 | EZH2 (0.38) | S1PR5 | |
| SCHEMBL12879987 | 0.73 | TACR3 (0.35) | MAPK14 | |
| SCHEMBL8059113 | 0.73 | TACR3 (0.35) | MAPK14 | |
| SCHEMBL8058110 | 0.72 | PDE4D (0.42) | — | |
| SCHEMBL31474623 | 0.72 | S1PR5 (0.35) | S1PR5GRM5S1PR3 | |
| SCHEMBL31491391 | 0.70 | ADORA1 (0.39) | AXLMERTKMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008788-A1 | AZA-FUSED RING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | SUZHOU ARK BIOPHARMACEUTICAL CO LTD (CN) | 2026-01-08 | — | — | US | disclosed |
| EP-4596554-A1 | AZA-FUSED RING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | Suzhou Arkbiopharmaceutical Co., Ltd. (CN) | 2025-08-06 | — | — | EP | disclosed |
| CN-119698422-A | Aza condensed ring compound, preparation method and medical application thereof | 苏州爱科百发生物医药技术有限公司 | 2025-03-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008788-A1 | AZA-FUSED RING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | PDE4B, PDE4A, CYP4A11 | S1PR5 1335/4885AXL 3435/4885MERTK 4553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.